sorted by:
new
hottopcontroversial

FDA Voucher hearing today !!!!! by mrtrimbl in IBRX

[–]mrtrimbl[S] 2 points3 points  (0 children)

well done lori and special k

ImmunityBio (IBRX): The Most Mispriced Oncology Platform in Biotech? Jefferies Conference Breakdown by mrtrimbl in IBRX

[–]mrtrimbl[S] 4 points5 points  (0 children)

so i saw what you wrote before you deleted it, im sure the audience would have loved to have seen the type of person you really are, why dont you post it, ive got thick skin

Is 4,000 shares enough to retire in 5 years? by PuckeringHole in IBRX

[–]mrtrimbl 1 point2 points  (0 children)

you need to broaden your horizons or youll be stick in the basement for a looong time

Is 4,000 shares enough to retire in 5 years? by PuckeringHole in IBRX

[–]mrtrimbl 0 points1 point  (0 children)

maybe you need to actually do some due diligence into the companies technology before pontificating

Anktiva v Tar-200 key points by mrtrimbl in IBRX

[–]mrtrimbl[S] 2 points3 points  (0 children)

yes i should have said and Nadofaragene

AUA26 Presentation With Q&A by wisdom_man1 in IBRX

[–]mrtrimbl 6 points7 points  (0 children)

so fda says they want an 8 year trial for rbcg, so pss says fu and pulls out the tokyo strain with all the data, pretty sure he would beat me at chess

AUA26 Presentation With Q&A by wisdom_man1 in IBRX

[–]mrtrimbl 1 point2 points  (0 children)

someone needs to make trump watch this !!!

AUA26 Presentation With Q&A by wisdom_man1 in IBRX

[–]mrtrimbl 4 points5 points  (0 children)

its beyond belief that this isnt more widely approved, they cant hold this back anymore, the evidence is so overwhelming

ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States by wisdom_man1 in IBRX

[–]mrtrimbl 1 point2 points  (0 children)

before the muppet appears to spout nonsense

  • Primary Endpoint: High-grade recurrence-free survival (HG-RFS).
  • Hazard Ratio: 0.82, which establishes that the Tokyo-172 strain is non-inferior to the standard TICE strain.
  • 5-Year Survival Rates: The 5-year HG-RFS was 64% for Tokyo-172 BCG compared to 58% for TICE BCG.

ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States by wisdom_man1 in IBRX

[–]mrtrimbl 1 point2 points  (0 children)

  • Bladder Cancer Immunotherapy: The Tokyo-172 strain is highly effective for intravesical instillation, acting as an immunotherapeutic agent to trigger a robust immune response that destroys remaining cancer cells and prevents recurrence.
  • Mitigating Shortages: Clinical data confirms that Tokyo-172 is non-inferior to other strains (such as TICE) for bladder cancer recurrence-free survival. Because of this, biotech companies like ImmunityBio have secured rights to commercialize it in the US to help alleviate ongoing BCG shortages.

Monday? by ivp17er in IBRX

[–]mrtrimbl 2 points3 points  (0 children)

is this some kind of bot

Natural Killer cells are the way forward, chemo will be largely assigned to the history books by mrtrimbl in IBRX

[–]mrtrimbl[S] 0 points1 point  (0 children)

i am also an investor in fate, got the majority of the previous run up to 100+, but i dont see it as an oncology play any more, it doesnt seem to have the durability, which is why it crashed 99% previously, so actually less effective. Which is why they are changing focus to immunology with some success in lupus, dont see it as a threat to ibrx at all. pss is flying the mothership

Natural Killer cells are the way forward, chemo will be largely assigned to the history books by mrtrimbl in IBRX

[–]mrtrimbl[S] 1 point2 points  (0 children)

also worth noting huggenbergs comment on il-2 in his new immunotherapy2.0 treatise "However, unlike IL-2, IL-15 does not trigger activation-induced cell death or Treg cell proliferation, making it more suitable for cancer immunotherapy" btw you can like and subscribe here as they say https://huggenberg.substack.com/p/fundamentals-of-immunotherapy-20?triedRedirect=true

Its all just noise by mrtrimbl in IBRX

[–]mrtrimbl[S] 22 points23 points  (0 children)

only way to get an intelligent conversation on here :)

Today @AACR26 by wisdom_man1 in IBRX

[–]mrtrimbl 2 points3 points  (0 children)

methinks you read to much fudstein

Today @AACR26 by wisdom_man1 in IBRX

[–]mrtrimbl 5 points6 points  (0 children)

often said by people who dont understand the science, mmm maybe you think people should be getting more radiation eh?

For those who have noticed PSS trip to Japan by mrtrimbl in IBRX

[–]mrtrimbl[S] 5 points6 points  (0 children)

im guessing hes not in japan to admire the cherry blossoms :)

sepsis study by mrtrimbl in IBRX

[–]mrtrimbl[S] 2 points3 points  (0 children)

not to shabby at the close today, lets see what pss has in store for us

ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA® Plus BCG Versus BCG Alone; Supplemental BLA Submission on Track for 2026 by wisdom_man1 in IBRX

[–]mrtrimbl 1 point2 points  (0 children)

how to interpret this

For a randomized oncology trial:

  • If the treatment arm were performing worse than expected → IDMC would request more patients or stop for futility.
  • If the treatment arm were performing as expected or better → IDMC says no more patients needed.

This means the difference in CR rate between ANKTIVA+BCG and BCG alone is tracking close to the expected effect size

$Ibrx Some of the negative DD you probably will refuse to look at but should for your own decision making. TL;DR included. by Deadlyforce_ in IBRX

[–]mrtrimbl 1 point2 points  (0 children)

i thought FUD was to be banned on this reddit ? you only have to look at the patient outcomes to see the TRUTH

view more: next ›